The insurance company is offering the guidance in response to continued popularity of the drugs which are commonly used for weight-loss management.
Over the past two years, GLP-1s have become one of the most popular medications in the United States. Due to medications’ impact on appetite and eating habits, they’ve become very popular weight loss drugs for many people who struggling with obesity. As such, demand for the drugs has increased, which has caused insurance companies to develop strategies on how to help their customers obtain these medications while also ensure that they are doing so in a healthy way.
Personify Health, a healthcare insurance provider, recently shared best practices for GLP-1s for employers who utilize Personify’s services.1 These practices are based on three recommendations:
In a press release, Presonify Health’s chief medical officer Jeffrey Jacques, MD, said, “The dozens of inquiries I've fielded in the past several months make it clear that management of GLP-1s and their associated cost burdens are a top priority for most employers today. Whether they select our Transform program, or a dedicated solution from our partner ecosystem, clients using our platform will experience a personalized program, combining 1:1 support and AI-driven technology that engages and empowers their populations. GLP-1s aren't going away–the list of health conditions they may be able to address is only expanding, so it's critical that employers carve a path forward. Our approach will remain relevant and effective, now and in the future."
Personify Health is a relatively new company, which was birthed last November when Virgin Pulse and Healthcomp merged. In February of this year, the two companies unveiled the new company brand.2
In a press release issued at the time, Personify Health’s chief marketing officer Erica Sniad Morgenstern said, “Our company's strengths around personalization, human centricity, and high-touch partnerships provide compelling and differentiated opportunities for the new brand. Personify Health emphasizes our commitment to creating health experiences that put people at the center of every interaction. With the global scale of our platform, we help millions of people feel connected and supported when navigating everything from daily wellbeing routines to health complexities."
In the same press release, Personify Health’s CEO Chris Michalak said, “Personify Health is focused on helping real people with real needs by enabling our clients to make better decisions about the health benefits they provide–and then making them easy for people to use. We are bringing more humanity to a category that is, unfortunately, all too often lacking it. Our personalized health platform delivers modern, engaging experiences that motivate people to manage, improve, and sustain their health–leading to better outcomes for themselves and their companies."
"We are on a mission to engage and empower people to lead healthier lives," Michalak added. "The introduction of our new company brand is the first step to achieving this purpose-driven goal that motivates our people and clients every day."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.